Mycosis fungoides

Critical Reviews in Oncology/Hematology

Volumn 65, Issue 2, 2008, Pages 172-182

  Zinzani, Pier Luigi ^a   Ferreri, Andrés J M ^b   Cerroni, Lorenzo ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Mycosis fungoides; Sezary syndrome; T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIPRURITIC AGENT; BEXAROTENE; BLEOMYCIN; CARMUSTINE; CD30 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; INTERFERON; INTERLEUKIN 12; METHOTREXATE; PENTOSTATIN; PREDNISONE; PSORALEN; RETINOIC ACID; RETINOID; STEROID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLONE; CUTANEOUS T CELL LYMPHOMA; ELECTRON THERAPY; ERYTHRODERMA; GASTROINTESTINAL TRACT; HISTOLOGY; HUMAN; LIFE EXPECTANCY; LIVER; LUNG; LYMPH NODE; MYCOSIS FUNGOIDES; OUTCOME ASSESSMENT; PHOTOTHERAPY; PROGNOSIS; PUVA; REVIEW; SEZARY SYNDROME; SPLEEN; VISCERA; WORLD HEALTH ORGANIZATION;

HUMANS; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 37549046840     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.08.004     Document Type: Review

References (100)

1. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
2. Weinstock M.A. A registry-based case-control study of mycosis fungoides. Ann Epidemiol 1 (1991) 533-539
3. Whittemore A.S., Holly E.A., Lee I.M., et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 81 (1989) 1560-1567
4. Hall W.W., Liu C.R., Schneewind O., et al. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 253 (1991) 317-320
5. Wood G.S., Salvekar A., Schaffer J., et al. Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma. J Invest Dermatol 107 (1996) 301-307
6. Herne K.L., Talpur R., Breuer-McHam J., Champlin R., and Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 101 (2003) 2132-2136
7. Nisce L.Z., Safai B., and Kim J.H. Effectiveness of once weekly total skin electron beam therapy in mycosis fungoides and Sezary syndrome. Cancer 47 (1981) 870-876
8. Johnson G.A., Dewald G.W., Strand W.R., and Winkelmann R.K. Chromosome studies in 17 patients with the Sezary syndrome. Cancer 55 (1985) 2426-2433
9. Karenko L., Hahtola S., Paivinen S., et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 65 (2005) 8101-8110
10. Massone C., Kodama K., Kerl H., and Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 29 (2005) 550-560
11. Ralfkiaer E., Wollf-Sneedorff A., Thomsen K., and Vejlsgaard G.L. Immunophenotypic studies in cutaneous T-cell lymphomas: clinical implications. Br J Dermatol 129 (1993) 655-659
12. Harmon C.B., Witzig T.E., Katzmann J.A., and Pittelkow M.R. Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 35 (1996) 404-410
13. Muche J.M., Lukowsky A., Asadullah K., Gellrich S., and Sterry W. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood 90 (1997) 1636-1642
14. Hoppe R.T., Wood G.S., and Abel E.A. Mycosis fungoides and the Sezary syndrome: pathology, staging, and treatment. Curr Probl Cancer 14 (1990) 293-371
15. Sanchez J.L., and Ackerman A.B. The patch stage of mycosis fungoides. Criteria for histologic diagnosis. Am J Dermatopathol 1 (1979) 5-26
16. Kim Y.H., Jensen R.A., Watanabe G.L., Varghese A., and Hoppe R.T. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (1996) 1309-1313
17. Bunn P.A.J., and Lamberg S.I. Report of the committee on staging and classification of cutaneous t-cell lymphomas. Cancer Treat Rep 63 (1979) 725-728
18. Wieselthier J.S., and Koh H.K. Sezary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 22 (1990) 381-401 [see comments]
19. Kim Y.H., Bishop K., Varghese A., and Hoppe R.T. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 131 (1995) 1003-1008
20. Epstein E.H.J., Levin D.L., Croft J.D.J., and Lutzner M.A. Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 51 (1972) 61-72
21. Tracey L., Villuendas R., Dotor A.M., et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 102 (2003) 1042-1050
22. Kulin P.A., Marglin S.I., Shuman W.P., Chew D.E., and Olerud J.E. Diagnostic imaging in the initial staging of mycosis fungoides and Sezary syndrome. Arch Dermatol 126 (1990) 914-918
23. Salhany K.E., Greer J.P., Cousar J.B., and Collins R.D. Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases. Am J Clin Pathol 92 (1989) 747-754
24. Kim Y.H., Chow S., Varghese A., and Hoppe R.T. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 135 (1999) 26-32
25. Wood G.S., Bahler D.W., Hoppe R.T., et al. Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma. J Invest Dermatol 101 (1993) 296-300
26. Sausville E.A., Eddy J.L., Makuch R.W., et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 109 (1988) 372-382
27. Beylot-Barry M., Sibaud V., Thiebaut R., et al. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol 117 (2001) 920-926
28. Fraser-Andrews E.A., Woolford A.J., Russell-Jones R., Seed P.T., and Whittaker S.J. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 114 (2000) 117-121
29. Kaye F.J., Bunn P.A.J., Steinberg S.M., et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (1989) 1784-1790
30. Zackheim H.S. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol 13 (1994) 202-206
31. Abel E.A., Sendagorta E., Hoppe R.T., and Hu C.H. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol 123 (1987) 897-901
32. Herrmann J.J., Roenigk H.H.J., Hurria A., et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (1995) 234-242
33. Ramsay D.L., Lish K.M., Yalowitz C.B., and Soter N.A. Ultraviolet-B phototherapy for early stage cutaneous T-cell lymphoma. Arch Dermatol 128 (1992) 931-933
34. Resnik K.S., and Vonderheid E.C. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J Am Acad Dermatol 29 (1993) 73-77
35. Roenigk H.H.J., Kuzel T.M., Skoutelis A.P., et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 (1990) 198S-205S
36. Boztepe G., Sahin S., Ayhan M., Erkin G., and Kilemen F. Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. J Am Acad Dermatol 53 (2005) 242-246
37. Gathers R.C., Scherschun L., Malick F., Fivenson D.P., and Lim H.W. Narrowband UVB phototherapy for early stage mycosis fungoides. J Am Acad Dermatol 47 (2002) 191-197
38. Diederen P.V., Van Weelden H., Sanders C.J., Toonstra J., and van Vloten W.A. Narrowband UVB and psoralen-UVA in the treatment of early stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 48 (2003) 215-219
39. El Mofty M., El Darouty M., Salonas M., et al. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early stage mycosis fungoides: a right-left comparative study. Photodermatol Photoimmunol Photomed 21 (2005) 281-286
40. Ghodsi S.Z., Hallaji Z., Balighi K., Safar F., and Chams-Davatchi C. Narrow-band UVB in the treatment of early stage mycosis fungoides: report of 16 patients. Clin Exp Dermatol 30 (2005) 376-378
41. Wood G.S., Abel E.A., Hoppe R.T., and Warnke R.A. Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation. J Am Acad Dermatol 14 (1986) 1006-1013
42. Breneman D., Duvic M., Kuzel T., et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 138 (2002) 325-332
43. Coors E.A., and von den D.P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 50 (2004) 363-367
44. de Quatrebarbes J., Esteve E., Bagot M., et al. Treatment of early stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (2005) 1117-1120
45. Deeths M.J., Chapman J.T., Dellavalle R.P., Zeng C., and Aeling J.L. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 52 (2005) 275-280
46. Demierre M.F., Vachon L., Ho V., et al. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early stage mycosis fungoides. Arch Dermatol 139 (2003) 624-628
47. Heald P., Mehlmauer M., Martin A.G., et al. Topical bexarotene therapy for patients with refractory or persistent early stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (2003) 801-815
48. Hoppe R.T. Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat Ther Oncol 25 (1991) 80-89
49. Quiros P.A., Jones G.W., Kacinski B.M., et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (1997) 1027-1035
50. Jones G.W., Tadros A., Hodson D.I., et al. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys 28 (1994) 839-845
51. Duvic M., Lemak N.A., Redman J.R., et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 34 (1996) 1022-1029
52. Jones G., McLean J., Rosenthal D., Roberts J., and Sauder D.N. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). J Am Acad Dermatol 26 (1992) 960-967
53. Kuzel T.M., Roenigk H.H.J., Samuelson E., et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 13 (1995) 257-263
54. Chinn D.M., Chow S., Kim Y.H., and Hoppe R.T. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (1999) 951-958
55. Wilson L.D., Licata A.L., Braverman I.M., et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 32 (1995) 987-995
56. Winkler C.F., Sausville E.A., Ihde D.C., et al. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. J Clin Oncol 4 (1986) 1094-1100
57. Holloway K.B., Flowers F.P., and Ramos-Caro F.A. Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 27 (1992) 367-378 [see comments]
58. Gottlieb S.L., Wolfe J.T., Fox F.E., et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 35 (1996) 946-957
59. Dreno B., Claudy A., Meynadier J., et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 125 (1991) 456-459
60. Marschalko M., Knobler R., Soos G., et al. Extracorporeal photopheresis in the therapy of Sezary syndrome. Orv Hetil 134 (1993) 1253-1257 [Hungarian]
61. Zackheim H.S., Kashani-Sabet M., and Hwang S.T. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in 29 patients. J Am Acad Dermatol 34 (1996) 626-631
62. Bunn P.A.J., Hoffman S.J., Norris D., Golitz L.E., and Aeling J.L. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121 (1994) 592-602
63. Grozea P.N., Jones S.E., McKelvey E.M., et al. Combination chemotherapy for mycosis fungoides: a southwest oncology group study. Cancer Treat Rep 63 (1979) 647-653
64. Rosen S.T., and Foss F.M. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin N Am 9 (1995) 1109-1116
65. Quaglino P., Fierro M.T., Rossotto G.L., Savoia P., and Bernengo M.G. Treatment of advanced mycosis fungoides/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 150 (2004) 327-336
66. Kuchnio M., Sausville E.A., Jaffe E.S., et al. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. Am J Clin Pathol 102 (1994) 856-860
67. Mercieca J., Matutes E., Dearden C., MacLennan K., and Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12 (1994) 2588-2593
68. Von Hoff D.D., Dahlberg S., Hartstock R.J., and Eyre H.J. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a southwest oncology group study. J Natl Cancer Inst 82 (1990) 1353-1355
69. Foss F.M., Ihde D.C., Breneman D.L., et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 10 (1992) 1907-1913
70. Bigler R.D., Crilley P., Micaily B., et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 7 (1991) 133-137
71. Guitart J., Wickless S.C., Oyama Y., et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138 (2002) 1359-1365
72. Masood N., Russell K.J., Olerud J.E., et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 47 (2002) 140-145
73. Molina A., Zain J., Arber D.A., et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 (2005) 6163-6171
74. Olavarria E., Child F., Woolford A., et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114 (2001) 624-631
75. Soligo D., Ibatici A., Berti E., et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant 31 (2003) 663-666
76. Knox S.J., Levy R., Hodgkinson S., et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 77 (1991) 20-30
77. Sacchi S., Russo D., Avvisati G., et al. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Haematologica 82 (1997) 106-121
78. Duvic M., Hymes K., Heald P., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (2001) 2456-2471
79. Duvic M., Martin A.G., Kim Y., et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma. Arch Dermatol 137 (2001) 581-593
80. Lundin J., Osterborg A., Brittinger G., et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-hodgkin's lymphoma. J Clin Oncol 16 (1998) 3257-3263
81. Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101 (2003) 4267-4272
82. Pangalis G.A., Dimopoulou M.N., Angelopoulou M.K., et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 18 (2001) 99-107
83. Hagberg H., Lundin J., Cavallin-Stahl E., et al. Phase 2 study of alemtuzumab (Campath-1H) in patients with advanced mycosis fungoides/Sèzary syndrome. Ann Oncol 13 Suppl 2 (2002) 85
84. Zinzani P.L., Alinari L., Tani M., et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90 (2005) 702-703
85. Olsen E., Duvic M., Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2001) 376-388
86. Talpur R., Jones D.M., Alencar A.J., et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126 (2006) 575-583
87. Dummer R., Hassel J.C., Fellenberg F., et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104 (2004) 1631-1638
88. Maier T., Tun-Kyi A., Tassis A., et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102 (2003) 2338-2344
89. Zinzani P.L., Baliva G., Magagnoli M., et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18 (2000) 2603-2606
90. Marchi E., Alinari L., Tani M., et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 104 (2005) 2437-2441
91. Wollina U., Dummer R., Brockmeyer N.H., et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (2003) 993-1001
92. Tsimberidou A.M., Giles F., Duvic M., Fayad L., and Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 100 (2004) 342-349
93. Tsimberidou A.M., Giles F.J., Duvic M., and Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 51 (2004) 200-204
94. Rook A.H., Kuzel T.M., and Olsen E.A. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 17 (2003) 1435-1448 ix
95. Duvic M., Talpur R., Chiao N., and Chiao J. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) [abstract]. Blood 102 (2003) 179a
96. Wysocka M., Benoit B.M., Newton S., et al. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104 (2004) 4142-4149
97. Munster P., Marchion D., Bicaku E., et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25 (2007) 1979-1985
98. Gojo I., Jiemjit A., Trepel J.B., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 (2007) 2781-2790
99. Undevia S.D., Kindler H.L., Janisch L., et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol 15 (2004) 1705-1711
100. Robey R.W., Zhan Z., Piekarz R.L., et al. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 12 (2006) 1547-1555